<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413567</url>
  </required_header>
  <id_info>
    <org_study_id>C-20000 A &amp; B</org_study_id>
    <nct_id>NCT02413567</nct_id>
  </id_info>
  <brief_title>Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes</brief_title>
  <official_title>Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fractyl Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fractyl Laboratories, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Fractyl Duodenal Mucosal Resurfacing (DMR)&#xD;
      Procedure for the treatment of Type 2 Diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2015</start_date>
  <completion_date type="Actual">September 18, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean reduction in HbA1c (glycated hemoglobin) from baseline at 24 weeks post-procedure</measure>
    <time_frame>24 weeks post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Device or procedure related Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs)</measure>
    <time_frame>24 weeks post-procedure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DMR Procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive the endoscopic DMR procedure in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DMR Procedure (Fractyl)</intervention_name>
    <description>Endoscopic procedure</description>
    <arm_group_label>DMR Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. 28 -75 years of age&#xD;
&#xD;
          2. Diagnosed with Type 2 Diabetes for less than 10 years&#xD;
&#xD;
          3. HbA1c of 7.5 - 10.0% (59-86 mmol/mol)&#xD;
&#xD;
          4. Body Mass Index (BMI) ≥ 24 and ≤ 40 kg/m2&#xD;
&#xD;
          5. On a minimum of 1 stable oral anti-diabetic medications with no changes in medication&#xD;
             in the previous 3 months prior to study entry&#xD;
&#xD;
          6. Willing to comply with study requirements and able to understand and comply with&#xD;
             informed consent&#xD;
&#xD;
          7. Sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Diagnosed with Type 1 Diabetes or with a history of ketoacidosis&#xD;
&#xD;
          2. Probable insulin production failure, defined as fasting C Peptide serum &lt;1ng/mL&#xD;
             (333pmol/l)&#xD;
&#xD;
          3. Current use of Insulin&#xD;
&#xD;
          4. Use of Glucagon like peptide (GLP)-1 analogues&#xD;
&#xD;
          5. Hypoglycemia unawareness or a history of severe hypoglycemia (at least 1 severe&#xD;
             hypoglycemic event, as defined by need for third-party-assistance, in the last year)&#xD;
&#xD;
          6. Known autoimmune disease, as evidenced by a positive anti glutamic acid decarboxylase&#xD;
             (GAD) test, including Celiac disease, or pre-existing symptoms of systemic lupus&#xD;
             erythematosus, scleroderma or other autoimmune connective tissue disorder&#xD;
&#xD;
          7. Previous gastrointestinal (GI) surgery that could affect the ability to treat the&#xD;
             duodenum such as subjects who have had a Bilroth 2, Roux-en-Y gastric bypass, or other&#xD;
             similar procedures or conditions&#xD;
&#xD;
          8. History of chronic or acute pancreatitis&#xD;
&#xD;
          9. Known active hepatitis or active liver disease&#xD;
&#xD;
         10. Symptomatic gallstones or kidney stones, acute cholecystitis or history of duodenal&#xD;
             inflammatory diseases including Crohn's Disease and Celiac Disease&#xD;
&#xD;
         11. History of coagulopathy, upper gastro-intestinal bleeding conditions such as ulcers,&#xD;
             gastric varices, strictures, congenital or acquired intestinal telangiectasia&#xD;
&#xD;
         12. Use of anticoagulation therapy (such as Warfarin) which cannot be discontinued for 7&#xD;
             days before and 14 days after the procedure&#xD;
&#xD;
         13. Use of P2Y12 inhibitors (clopidrogel, pasugrel, ticagrelor) which cannot be&#xD;
             discontinued for 14 days before and 14 days after the procedure. Use of aspirin is&#xD;
             allowed.&#xD;
&#xD;
         14. Unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during treatment&#xD;
             through 4 weeks post procedure phase&#xD;
&#xD;
         15. Taking corticosteroids or drugs known to affect GI motility (e.g. Metoclopramide)&#xD;
&#xD;
         16. Receiving weight loss medications such as Meridia, Xenical, or over the counter weight&#xD;
             loss medications&#xD;
&#xD;
         17. Persistent Anemia, defined as Hgb &lt; 10 mg/dl&#xD;
&#xD;
         18. Estimated glomerular filtration rate (eGFR) or Modification of Diet in Renal Disease&#xD;
             (MDRD) &lt;30 ml/min/1,73m^2&#xD;
&#xD;
         19. Active systemic infection&#xD;
&#xD;
         20. Active malignancy within the last 5 years&#xD;
&#xD;
         21. Not potential candidates for surgery or general anesthesia&#xD;
&#xD;
         22. Active illicit substance abuse or alcoholism&#xD;
&#xD;
         23. Those who are pregnant, nursing or expect to become pregnant over the course of the&#xD;
             study&#xD;
&#xD;
         24. Participating in another ongoing clinical trial&#xD;
&#xD;
         25. Any other mental or physical condition which, in the opinion of the Investigator,&#xD;
             makes the subject a poor candidate for clinical trial participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Clinico de Obesidad</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore, Policlinico A. Gemelli</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

